Tag: stock option

TORONTO, June 02, 2026 (GLOBE NEWSWIRE) -- FirstService Corporation (TSX and NASDAQ: FSV) (“FirstService”) announced today that, further to its previously announced acceptance by the Toronto Stock Exchange (the “TSX”) of a notice filed by FirstService of its intention to make a normal course issuer bid (the “NCIB”) with respect to its outstanding common shares, it has received approval from the TSX to amend the NCIB (the “Amended NCIB”), effective on June 4, 2026. The Amended NCIB will increase the maximum number of common shares that may be repurchased from 1,600,000, representing 3.9% of the “public float” of common shares as of August 12, 2025, to 4,118,199, representing 10% of the “public float” of common shares as of August 12, 2025, the maximum amount allowable under the rules of the TSX. No other terms of the NCIB have been amended. Under the NCIB, as of May 31, 2026, FirstService has repurchased for cancellation an aggregate of 931,182 common shares at an average price of US$132.38 per share (or a total of US$123.3 million).

REGISTRATION OF THE COMBINATION OF SHARES OF DIGITALIST GROUP PLC, AND ADJUSTMENT OF THE MAXIMUM NUMBERS OF SHARES IN THE COMPANY AVAILABLE FOR SUBSCRIPTION UNDER THE COMPANY’S CONVERTIBLE LOAN INSTRUMENTS AND THE 2021 STOCK OPTION PROGRAM, AS WELL AS THE SUBSCRIPTION PRICES

SARASOTA, Fla., Aug. 14, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO Fertility” or the “Company”), a healthcare services fertility company focused on expanding access to advanced treatment through the establishment, acquisition and operation of fertility clinics and related businesses and technologies, today announced second quarter 2025 financial results.

A CONFERENCE CALL IS SCHEDULED FOR FRIDAY, AUGUST 15, 2025, 11:00AM EASTERN TIME

Conference call to follow tomorrow, August 14 at 5 PM EST

WOODLAND PARK, N.J., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Anterix (NASDAQ: ATEX) today announced its first quarter fiscal 2026 results and filed its Form 10-Q for the three months ended June 30, 2025. The Company also issued an update on its Demonstrated Intent metric which can be found on Anterix’s website at https://investors.anterix.com/events-presentations.

Q2 2025 revenue of $40.2 million
Q2 2025 Adjusted EBITDA of $4.7 million and GAAP Net Income of $0.5 million
Paid off $14.9 million balance of 2025 Convertible Notes
Entered into a $15.0 million undrawn working capital facility for further operating flexibility and liquidity